Quanterix (NASDAQ:QTRX) Announces Quarterly Earnings Results

Key Points

• Quanterix missed quarterly expectations: The company reported an adjusted loss of $1.04 per share versus the consensus loss estimate of $0.41, while revenue of $32.91 million fell short of the $37.46 million forecast.
• Shares remain under pressure: QTRX opened at $4.03, with a market capitalization of approximately $189.85 million and a 52-week trading range of $2.39 to $8.77.
• Analyst sentiment is cautious: Analysts have an average “Reduce” rating and a consensus price target of $4.00 after Canaccord Genuity and TD Cowen cut their targets; institutional investors own 86.48% of the stock.

Quanterix (NASDAQ:QTRX - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.63), FiscalAI reports. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%.The firm had revenue of $32.91 million for the quarter, compared to the consensus estimate of $37.46 million.

Quanterix Stock Performance

Shares of Quanterix stock opened at $4.03 on Monday. Quanterix has a 52 week low of $2.39 and a 52 week high of $8.77. The stock has a market cap of $189.85 million, a PE ratio of -1.71 and a beta of 1.07. The company's 50-day moving average price is $3.70 and its two-hundred day moving average price is $4.20.

Institutional Trading of Quanterix

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd acquired a new position in shares of Quanterix in the 4th quarter worth $138,000. ExodusPoint Capital Management LP acquired a new position in shares of Quanterix in the 4th quarter valued at $153,000. LPL Financial LLC acquired a new position in shares of Quanterix in the 4th quarter valued at $158,000. Brevan Howard Capital Management LP increased its stake in Quanterix by 60.2% in the 3rd quarter. Brevan Howard Capital Management LP now owns 23,244 shares of the company's stock worth $126,000 after purchasing an additional 8,739 shares in the last quarter. Finally, Intech Investment Management LLC raised its holdings in Quanterix by 13.4% during the 3rd quarter. Intech Investment Management LLC now owns 19,161 shares of the company's stock worth $104,000 after buying an additional 2,268 shares during the period. 86.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Quanterix from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Canaccord Genuity Group reduced their price objective on Quanterix from $8.00 to $4.00 and set a "hold" rating for the company in a research report on Monday, April 20th. Weiss Ratings downgraded Quanterix from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, May 13th. Finally, TD Cowen lowered their price objective on Quanterix from $7.00 to $4.00 and set a "hold" rating for the company in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus price target of $4.00.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source